Keywords
hyperglycemia
diabetic ketoacidosis
SARS-CoV-2
How to Cite
Abstract
In modern society Diabetes Mellitus (DM) is one of the topic health issues. DM is one of the main risk factors for severe diseases and chronic complications that may arise from COVID-19. There are some reasons why patients with DM may be more susceptible to the severe effects of COVID-19: unstable blood glucose level, weakened immune system, greater susceptibility to infections, micro- and macrovascular damage. Current studies on the COVID-19 pandemic confirm that DM is the most common associated disease in patients with COVID-19. There is increasing evidence that COVID-19 can lead to the development of type 1 and type 2 DM. However, it is important to note that the conclusions are based on a limited data in this review, and now require further research to confirm. More detailed and objective studies are needed to determine more accurate detection rate of newly diagnosed DM (NDD). The authors conducted a review of literature sources to identify NDD due to СОVID-19. In this review, we aimed to highlight the two-way relationship between DM and COVID-19 by examining the published data and their generalizations on NDD after COVID-19. According to the results of analysis it was concluded that patients had diabetes were being associated with a higher risk of acquiring COVID-19, placing them at greater risk for the severity and lethality of COVID-19, patients had an elevated incidence risk for NDD after COVID-19.
Keywords: newly diagnosed diabetes mellitus, hyperglycemia, diabetic ketoacidosis, SARS-CoV-2.
References
Dysted MP, Esztergalyos B, Gautam S, Helman B, Pinkepank M, Randi A, et al. IDF Diabetes Atlas. 10th ed. Ed. Magliano DJ, Boyko EJ, et al. International Diabetes Associаtion; 2021. 141 p. Available at: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
Unnikrishnan R & Misra A. Diabetes and COVID19: a bidirectional relationship. Nutrition & diabetes. 202;11(1):21. DOI: 10.1038/s41387-021-00163-2. PMID: 34168110.
Sharma P, Behl T, Sharma N, Singh S, Grewal AS, Albarrati A, et al. COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality. Biomed Pharmacother. 2022;151:113089. DOI: 10.1016/j.biopha.2022.113089. PMID: 35569351.
Vardavas CI, Mathioudakis AG, Nikitara K, Stamatelopoulos K, Georgiopoulos G, Phalkey R, et al. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. Eur Respir Rev. 2022;31(166): 220098. DOI: 10.1183/16000617.0098-2022. PMID: 36323422.
Banerjee M, Pal R, Dutta, S. Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis. Primary care diabetes. 2022;16(4):591–3. DOI: 10.1016/j.pcd.2022.05.009. PMID: 35654679.
Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of β-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. Cells. 2020;9(11): 2475. DOI: 10.3390/cells9112475. PMID: 33202960.
Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. JAMA network open. 2022;5(9):e2233014. DOI: 10.1001/jamanetworkopen.2022.33014. PMID: 36149658.
Gottesman BL, Yu J, Tanaka C, Longhurst CA, Kim JJ. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. JAMA pediatrics. 2022;176(4):414-5. DOI: 10.1001/jamapediatrics.2021.5801. PMID: 35072727.
Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen E A, Perrine CG, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020 – June 28, 2021. MMWR. Morbidity and mortality weekly report. 2022;71(2):59-65. DOI: 10.15585/mmwr.mm7102e2. PMID: 35025851.
Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC, et al. The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection. Diabetes Care. 2022;45(4):782-8. DOI: 10.2337/dc21-1686. PMID: 35085391.
Ssentongo P, Zhang Y, Witmer L, Chinchilli VM, Ba DM. Association of COVID-19 with diabetes: a systematic review and meta-analysis. Scientific reports. 2022;12(1),:20191. DOI: 10.1038/s41598-022-24185-7. PMID: 36418912.
Maestre-Muniz MM, Arias A, Mata-Vazquez E, Martin-Toledano M, Lopez-Larramona G, Ruiz-Chicote AM, et al. Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. J Clin Med. 2021;10(13):2945. DOI: 10.3390/jcm10132945. PMID: 34209085.
Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes care. 2020;43(11):170-1. DOI: 10.2337/dc20-1551. PMID: 32816997.
McKeigue PM, McGurnaghan S, Blackbourn L, Bath LE, McAllister DA, Caparrotta TM, et al. Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland. Diabetes care. 2023;46(5):921-8. DOI: 10.2337/dc22-0385. PMID: 35880797.
Salmi H, Heinonen S, Hastbacka J, Laaperi M, Rautiainen P, Miettinen PJ, et al. New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Archives of disease in childhood. 2022;107(2):180-5. DOI:10.1136/archdischild-2020- 321220. PMID: 34045208.
Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022;65(6):949-54. DOI: 10.1007/s00125-022-05670-0. PMID: 35292829.
Farag AA, Hassanin HM, Soliman HH, Sallam A, Sediq AM, Elbaser ESA, Elbanna K. Newly Diagnosed Diabetes in Patients with COVID-19: Different Types and Short-Term Outcomes. Trop. Med. Infect. Dis. 2021;6(3):142. DOI: 10.3390/tropicalmed6030142.
Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes, obesity & metabolism. 2021;23(3):870-4. DOI: 10.1111/dom.14269. PMID: 33245182.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.